Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-15025 |
Synonyms | |
Therapy Description |
BGB-15025 is a small molecule inhibitor of MAP4K1 (HPK1,MEKKK1), which may prevent immunosuppression in the tumor microenvironment and activate anti-tumor immune response (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-15025 | BGB15025|BGB 15025 | MAP4K1 Inhibitor 7 | BGB-15025 is a small molecule inhibitor of MAP4K1 (HPK1,MEKKK1), which may prevent immunosuppression in the tumor microenvironment and activate anti-tumor immune response (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04649385 | Phase I | BGB-15025 BGB-15025 + Tislelizumab | BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | NZL | AUS | 2 |